{
    "xml": "<topic id=\"PHP767\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/milrinone\" basename=\"milrinone\" title=\"MILRINONE\">\n<title>MILRINONE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1039\" namespace=\"/interactions/list-of-drug-interactions/phosphodiesterase-type-3-inhibitors/milrinone\">Milrinone</xref>\n</p>\n<data name=\"vtmid\">108480007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_252425805\" title=\"Phosphodiesterase type-3 inhibitors\">Phosphodiesterase type-3 inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP64037\" outputclass=\"drugAction\" rev=\"1.6\" parent=\"/drugs/milrinone\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Milrinone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63982\" outputclass=\"indicationsAndDose\" rev=\"1.15\" parent=\"/drugs/milrinone\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Short-term treatment of severe congestive heart failure unresponsive to conventional maintenance therapy (not immediately after myocardial infarction)</p>\n<p outputclass=\"therapeuticIndication\">Acute heart failure, including low output states following heart surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 50&#8239;micrograms/kg, given over 10 minutes, followed by (by intravenous infusion) 375&#8211;750&#8239;nanograms/kg/minute usually given following surgery for up to 12 hours or in congestive heart failure for 48-72 hours; maximum 1.13&#8239;mg/kg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64059\" outputclass=\"contraindications\" rev=\"1.5\" parent=\"/drugs/milrinone\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Severe hypovolaemia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64072\" outputclass=\"cautions\" rev=\"1.5\" parent=\"/drugs/milrinone\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Correct hypokalaemia</ph>; <ph outputclass=\"caution\">heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66245\" outputclass=\"interactions\" rev=\"1.5\" parent=\"/drugs/milrinone\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (phosphodiesterase type-3 inhibitors).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66203\" outputclass=\"sideEffects\" rev=\"1.6\" parent=\"/drugs/milrinone\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Ectopic beats</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias)</ph>; <ph outputclass=\"sideEffect\">ventricular tachycardia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Chest pain</ph>; <ph outputclass=\"sideEffect\">hypokalaemia</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">tremor</ph>; <ph outputclass=\"sideEffect\">ventricular fibrillation</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaphylaxis</ph>; <ph outputclass=\"sideEffect\">bronchospasm</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66233\" outputclass=\"pregnancy\" parent=\"/drugs/milrinone\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64084\" outputclass=\"breastFeeding\" parent=\"/drugs/milrinone\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66211\" outputclass=\"renalImpairment\" parent=\"/drugs/milrinone\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose and monitor response if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;consult product literature for details.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65295\" outputclass=\"monitoringRequirements\" parent=\"/drugs/milrinone\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count and hepatic enzymes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64128\" outputclass=\"directionsForAdministration\" rev=\"1.10\" parent=\"/drugs/milrinone\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Avoid extravasation.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous injection</i>, may be given either undiluted or diluted before use.</p>\n<p>For <i>intravenous infusion</i> (Primacor<tm tmtype=\"reg\"/>) give continuously in Glucose 5% or Sodium chloride 0.9%; dilute to a suggested concentration of 200&#8239;micrograms/mL.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61542\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/milrinone\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Sustained haemodynamic benefit has been observed after administration of phosphodiesterase type-3 inhibitors, but there is no evidence of any beneficial effect on survival.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP767-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/milrinone\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: solution for infusion</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75940\" title=\"Solution for injection\" namespace=\"/drugs/milrinone/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1039\" namespace=\"/interactions/list-of-drug-interactions/phosphodiesterase-type-3-inhibitors/milrinone\" title=\"Milrinone\" count=\"1\" rel=\"link\">Milrinone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75940\" namespace=\"/drugs/milrinone/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP767",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/milrinone",
    "basename": "milrinone",
    "title": "MILRINONE",
    "interactants": [
        {
            "id": "bnf_int_1039",
            "label": "Milrinone"
        }
    ],
    "vtmid": "108480007",
    "drugClassification": [
        "Phosphodiesterase type-3 inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Milrinone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.",
                "html": "<p>Milrinone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Short-term treatment of severe congestive heart failure unresponsive to conventional maintenance therapy (not immediately after myocardial infarction)",
                        "html": "Short-term treatment of severe congestive heart failure unresponsive to conventional maintenance therapy (not immediately after myocardial infarction)"
                    },
                    {
                        "textContent": "Acute heart failure, including low output states following heart surgery",
                        "html": "Acute heart failure, including low output states following heart surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection"
                    ],
                    "textContent": "Initially by intravenous injection",
                    "html": "Initially by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 50 micrograms/kg, given over 10 minutes, followed by (by intravenous infusion) 375&#8211;750 nanograms/kg/minute usually given following surgery for up to 12 hours or in congestive heart failure for 48-72 hours; maximum 1.13 mg/kg per day.",
                        "html": "<p>Initially 50&#8239;micrograms/kg, given over 10 minutes, followed by (by intravenous infusion) 375&#8211;750&#8239;nanograms/kg/minute usually given following surgery for up to 12 hours or in congestive heart failure for 48-72 hours; maximum 1.13&#8239;mg/kg per day.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Severe hypovolaemia",
                "html": "Severe hypovolaemia"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Correct hypokalaemia",
                "html": "Correct hypokalaemia"
            },
            {
                "type": "cautions",
                "textContent": "heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction",
                "html": "heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (phosphodiesterase type-3 inhibitors).",
                "html": "<p>Appendix 1 (phosphodiesterase type-3 inhibitors).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Ectopic beats",
                        "html": "Ectopic beats",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias)",
                        "html": "supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "ventricular tachycardia",
                        "html": "ventricular tachycardia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Chest pain",
                        "html": "Chest pain",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hypokalaemia",
                        "html": "hypokalaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "ventricular fibrillation",
                        "html": "ventricular fibrillation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Anaphylaxis",
                        "html": "Anaphylaxis",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "bronchospasm",
                        "html": "bronchospasm",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose and monitor response if eGFR less than 50 mL/minute/1.73 m2&#8212;consult product literature for details.",
                "html": "<p>Reduce dose and monitor response if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>&#8212;consult product literature for details.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count and hepatic enzymes.",
                "html": "<p>Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count and hepatic enzymes.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Avoid extravasation.",
                "html": "<p>Avoid extravasation.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous injection, may be given either undiluted or diluted before use.\n\nFor intravenous infusion (Primacor) give continuously in Glucose 5% or Sodium chloride 0.9%; dilute to a suggested concentration of 200 micrograms/mL.",
                "html": "<p>For <i>intravenous injection</i>, may be given either undiluted or diluted before use.</p><p>For <i>intravenous infusion</i> (Primacor<tm tmtype=\"reg\"/>) give continuously in Glucose 5% or Sodium chloride 0.9%; dilute to a suggested concentration of 200&#8239;micrograms/mL.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Sustained haemodynamic benefit has been observed after administration of phosphodiesterase type-3 inhibitors, but there is no evidence of any beneficial effect on survival.",
                "html": "<p>Sustained haemodynamic benefit has been observed after administration of phosphodiesterase type-3 inhibitors, but there is no evidence of any beneficial effect on survival.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "solution for infusion"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75940",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1039",
                "label": "Milrinone",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75940",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}